TABLE 4.

Performance characteristics of fecal immunochemical test (FIT) compared with guaiac fecal occult blood test (gFOBT)

Author (ref), year	Study population	Comparisons	Sensitivity, %	Specificity, %	Positivity, %	PPV, %
van Rossum et al (19), 2008	20,623 participants 50–75 years of age	OC-Sensor* FIT (n=10,322) vs Hemoccult II† gFOBT (n=10,301)	Not reported	CRC FIT: 95.8, gFOBT: 98.1; AA1 FIT: 97.1, gFOBT: 98.7	FIT: 5.5, gFOBT: 2.4	CRC FIT: 8.6, gFOBT: 10.7; AA1 FIT: 37.9 gFOBT: 39.8
Hol et al (17), 2009	10,011 participants 50–74 years of age	OC-Sensor FIT (n=5007) vs Hemoccult II gFOBT (n=5,004)	Not reported	CRC FIT: 95.8, gFOBT: 97.6; AA2 FIT: 97.8, gFOBT: 98.5	FIT: 4.8, gFOBT:2.8	CRC FIT: 10, gFOBT:10; AA2 FIT: 53, gFOBT: 45
Park et al (23), 2010	770 participants 50–75 years of age completed both tests concurrently	OC-Sensor Micro* FIT vs Hemoccult II gFOBT	CRC FIT: 92.3 gFOBT: 30.8; AA: FIT: 33.9 gFOBT: 13.6	CRC FIT: 90.1, gFOBT: 92.4; AA4 FIT: 90.6, gFOBT: 92.4	FIT: 11.2, gFOBT: 7.9	CRC FIT: 12.8, gFOBT: 6.7; AA4 FIT: 23.3, gFOBT: 13.1
Allison et al (20), 2007	5932 participants ≥50 years of age completed both tests concurrently	FlexSure OBT†/Hemoccult ICT† FIT vs Hemoccult SENSA† gFOBT	CRC FIT: 81.8, gFOBT: 64.3; AA: FIT: 29.5, FOBT: 41.3	CRC FIT: 96.9, gFOBT: 90.1; AA3 FIT: 97.3, gFOBT: 90.6	FIT: 3.2, gFOBT: 10.1	CRC FIT: 5.2, gFOBT: 1.5; AA3 FIT: 19.1, gFOBT: 8.9

^*Eiken Chemical Company, Ltd, Japan;

^†Beckman Coulter Inc, USA.

AA Advanced adenoma (AA¹ Adenoma ≥10 mm with high-grade dysplasia or with a villous component ≥20%; AA² Adenoma ≥10 mm with high-grade dysplasia or with a villous component ≥25%; AA³ Tubular, villous, or tubulovillous adenomas ≥10 mm; AA⁴ Tubular adenomas ≥10 mm or tubulovillous or villous adenomas, or those with high-grade dysplasia regardless of size);

CRC Colorectal cancer; NR Not reported; ref Reference; vs Versus. All results at manufacturers’ suggested cut-off (100 ng/mL).